<https://rdf.molmedb.upol.cz/reference/ref883> <http://purl.org/dc/terms/subject> <https://identifiers.org/molmedb/MM17174>;
	<http://purl.org/ontology/bibo/doi> "10.1124/jpet.108.146225"^^<http://www.w3.org/2001/XMLSchema#string>;
	<http://purl.org/dc/terms/subject> <https://rdf.molmedb.upol.cz/transporter/target2>,
		<https://identifiers.org/molmedb/MM17584>,
		<https://identifiers.org/molmedb/MM16699>,
		<https://identifiers.org/molmedb/MM495866>,
		<https://identifiers.org/molmedb/MM00382>,
		<https://identifiers.org/molmedb/MM495866.1>;
	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://purl.org/dc/terms/BibliographicResource>;
	<http://purl.org/dc/terms/bibliographicCitation> "Minuesa G, Volk C, Molina-Arcas M, Gorboulev V, Erkizia I, Arndt P, Clotet B, Pastor-Anglada M, Koepsell H, Martinez-Picado J.: Transport of lamivudine [(-)-beta-L-2',3'-dideoxy-3'-thiacytidine] and high-affinity interaction of nucleoside reverse transcriptase inhibitors with human organic cation transporters 1, 2, and 3. J Pharmacol Exp Ther, Volume 329 (1), 2009"^^<http://www.w3.org/2001/XMLSchema#string>;
	<http://purl.org/ontology/bibo/pmid> "19141712"^^<http://www.w3.org/2001/XMLSchema#string> .
<https://rdf.molmedb.upol.cz/transporter/tra32370> <http://www.w3.org/ns/prov#hadPrimarySource> <https://rdf.molmedb.upol.cz/reference/ref883> .
<https://rdf.molmedb.upol.cz/transporter/tra32130> <http://www.w3.org/ns/prov#hadPrimarySource> <https://rdf.molmedb.upol.cz/reference/ref883> .
<https://rdf.molmedb.upol.cz/transporter/tra32411> <http://www.w3.org/ns/prov#hadPrimarySource> <https://rdf.molmedb.upol.cz/reference/ref883> .
<https://rdf.molmedb.upol.cz/transporter/tra32412> <http://www.w3.org/ns/prov#hadPrimarySource> <https://rdf.molmedb.upol.cz/reference/ref883> .
<https://rdf.molmedb.upol.cz/transporter/tra32725> <http://www.w3.org/ns/prov#hadPrimarySource> <https://rdf.molmedb.upol.cz/reference/ref883> .